Gilead Sciences has made a deal to buy a new medicine called RP-3467 from Repare Therapeutics. This medicine is designed to stop a certain part of cells called polymerase theta (Polθ) from working. The deal includes a big payment upfront and more money if the drug does well in tests. This is good news for Gilead because it shows they are working on new treatments. For Repare, it means they get money to keep doing research. This deal is important because it shows that companies are still investing in new drugs, even when the economy is uncertain.